In a recent brief to the Patent Trial and Appeal Board (PTAB), Pfizer and BioNTech (Pfizer) told PTAB judges that Moderna’s dismissal of prior art listed in Pfizer’s August 2023 petition for inter partes review (IPR) of Moderna’s patent on mRNA vaccine technology is inconsistent with its declarations to the Food and Drug Administration (FDA) during the drug approval process. According to the brief, when Moderna was seeking approval for its COVID-19 vaccines, the company “candidly represented to the FDA that prior studies for related vaccines…supported an expectation of safety and efficacy. But now, faced with invalidating vaccine prior art…Moderna wrongly casts the same vaccine prior art as irrelevant.” The brief referred to this as a “litigation-driven one-eighty.”
Recent Posts
- Other Barks and Bites for Friday, May 10: Bipartisan Congress Members Call for GAO Study on March-In Proposal; USPTO Warns Trademark Applicants of Data Leak; Supreme Court Rejects Time Limit on Copyright Damages
- The World’s AI Companies Are Killing Trust in the Technology
- SCOTUS Rejects Three-Year Limit on Copyright Damages But Sidesteps Accrual Question
- G+ Communications v. Samsung: The Perils of Being ‘Half-Committed’ to FRAND
- Four Factors to Consider When Deciding Whether to Use Trade Secrets